Skip to main navigation
  • About
    • Our Vision
    • Our Approach
    • Our Team
  • Pipeline
    • DARE-BV1
    • OVAPRENE®
    • Sildenafil Cream, 3.6%
  • Partners
  • Consumers
  • Investors
    • Overview
    • Press Releases
    • Presentation, Events & Webcasts
    • Stock Information
      • Stock Quote & Chart
      • Historic Stock Lookup
      • Analyst Coverage
    • Financial Information
      • Financials Overview
      • SEC Filings
      • Annual Reports & Proxies
      • Quarterly Results
    • Corporate Governance
      • Documents & Charters
    • Contact
  • Careers
  • Contact Us
    Dare Biosciences
    • Investors
    • Press releases
    • Presentations, Events & Webcasts
    • Stock information
    • Financial Information
    • Corporate governance
    • Contact

    Press Releases

    Press Releases

    04-20-2023
    Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
    04-19-2023
    David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
    04-18-2023
    Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therapy
    04-17-2023
    Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
    03-30-2023
    Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
    03-23-2023
    Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
    03-01-2023
    Daré Bioscience to Present at the 35th Annual Roth Conference
    02-22-2023
    Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
    02-01-2023
    Daré Bioscience to Participate in Three February Conferences
    01-26-2023
    Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms

    Pagination

    • First page « first
    • Previous page ‹ previous
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Next page next ›
    • Last page last »
    Displaying 31 - 40 of 41
    • Request email alerts |
    • Print this page |
    • Search investor site |

    © 2023 by Daré Bioscience | Daré Bioscience® is a registered trademark of Daré Bioscience, Inc.

    Privacy Policy | Terms of Service | COI Policy |

    Scroll to top